Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

• Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL)
• Relapsed or refractory after at least 1 regimen of standard therapy
• Prior therapy may include high-dose chemotherapy with autologous stem cell transplantation (ASCT) or immunotherapy
• Bidimensionally measurable disease
• At least 1 lesion at least 1.5 cm by CT scan
• No primary or secondary CNS lymphoma
• No HIV-related lymphoma
• No known or suspected transformed lymphoma (prior or concurrent)
• No bulky disease (i.e., any single mass greater than 10.0 cm)
• No pleural effusion with positive cytology for lymphoma
• Most recent pathology specimen available for collection
• No rapid disease progression or symptoms that indicate disease progression requiring rapid intervention within the past 2 weeks (e.g., severe shortness of breath, severe pain, or gastrointestinal or genitourinary obstruction)

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• At least 4 months

Hematopoietic

• Absolute neutrophil count at least 1,000/mm3
• Platelet count at least 50,000/mm3 (transfusion independent)
• Hemoglobin at least 9.0 g/dL

Hepatic

• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST and ALT less than 5 times ULN
• Hepatitis B surface antigen negative
• Hepatitis C negative

Renal

• Creatinine no greater than 2 times ULN

Other

• HIV negative
• No other primary malignancy within the past 3 years except squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or stage I prostate cancer
• No other serious nonmalignant condition that would preclude study
• No serious infection
• No known human antichimeric antibodies or human antihuman antibody positivity
• No type 1 hypersensitivity or anaphylactic reactions to murine proteins
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 6 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics
• At least 4 weeks since prior immunotherapy (unless clearly progressing)
• At least 12 weeks since prior ASCT

Chemotherapy

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (unless clearly progressing)

Endocrine therapy

• Not specified

Radiotherapy

• No prior radioimmunotherapy

Surgery

• At least 4 weeks since prior major surgery (unless patient has fully recovered)

Other

• At least 30 days since prior enrollment in clinical trials involving investigational devices or drugs
• No concurrent enrollment in other clinical trials involving investigational devices or drugs
• No concurrent investigational agents for disease other than NHL